

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) <i>#4</i>			Application Number	09/997,447	
			Filing Date	November 30, 2001	
			First Named Inventor	Nathan Andrew Shapira	
			Art Unit	1614	
			Examiner Name	<i>Spivack</i>	
Sheet	1	of	4	Attorney Docket Number	UF-260XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>PS</i>	U1	US-5,753,694	05-19-1998	Shank	<i>All</i>
<i>PS</i>	U2	US-5,760,006	06-02-1998	Shank et al.	<i>All</i>
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature	<i>Phillip Spivack</i>	Date Considered	<i>9/3/03</i>
--------------------	------------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/997,447	
			Filing Date	November 30, 2001	
			First Named Inventor	Nathan Andrew Shapira	
			Group Art Unit	1614	
			Examiner Name	(Unassigned)	
Sheet	2	of	4	Attorney Docket Number	UF-260XC1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
PS	R1	BURTON, L. and HARDEN, C., "Effect of Topiramate on Attention," <i>Epilepsy Research</i> , 1997, pp. 29-32, vol. 27, Pub: Elsevier Science B.V.			
PS	R2	CARREL, A.L., et al., "Growth Hormone Improves Body Composition, Fat Utilization, Physical Strength and Agility, and Growth in Prader-Willi Syndrome: A Controlled Study," <i>J. Pediatrics</i> , 1999, pp. 215-221, vol. 134, Pub: Mosby, Inc.			
PS	R3	CRAWFORD, P., "An Audit of Topiramate Use in a General Neurology Clinic," <i>Seizure</i> , 1998, pp. 207-11, vol. 7, Pub: British Epilepsy Association.			
PS	R4	DAVANZO, P.A. and King, B.H., "Open Trial of Lamotrigine in the Treatment of Self-Injurious Behavior in an Adolescent with Profound Mental Retardation," <i>J. of Child & Adolescent Psychopharmacology</i> , 1996, pp. 273-9, vol. 6, no. 4, Pub: Mary Ann Liebert, Inc.			
PS	R5	DONOVAN, S.J., et al., "Divalproex Treatment for Youth with Explosive Temper and Mood Lability: A Double-Blind, Placebo-Controlled Crossover Design," <i>Am J Psychiatry</i> , 2000, pp. 818-820, vol. 157, no. 5, Pub: Unknown.			
PS	R6	DYKENS, E.M. and Hodapp, R.M., "Treatment Issues in Genetic Mental Retardation Syndromes," <i>Professional Psychology: Research & Practice</i> , 1997, pp. 263-70, vol. 28, no. 3, Pub: American Psychological Association, Inc.			
PS	R7	EMERSON, E., et al., "The Prevalence of Challenging Behaviors: A Total Population Study," <i>Res. In Developmental Disabilities</i> , 2001, pp. 77-93, vol. 22, Pub: Elsevier Science Ltd.			
PS	R8	FAUGHT, E., et al., "Topiramate Placebo-Controlled Dose-Ranging Trial in Refractory Partial Epilepsy Using 200-, 400-, and 600-mg Daily Dosages," <i>Neurology</i> , 1996, pp. 1684-1690, vol. 46, Pub: American Academy of Neurology.			
PS	R9	GERBER, P.E., et al., "Factors Associated with Behavioral and Cognitive Abnormalities in Children Receiving Topiramate," <i>Pediatric Neurology</i> , 2000, pp. 200-3, vol. 22, no. 3, Pub: Elsevier Science Inc.			
PS	R10	GLENN, C.C., et al., "Genomic Imprinting: Potential Function and Mechanisms Revealed by the Prader-Willi and Angelman Syndromes," <i>Molecular Human Reproduction</i> , 1997, pp. 321-332, vol. 3, no. 4, Pub: European Society for Human Reproduction and Embryology.			
PS	R11	GOLDSMITH, T., et al., "Conceptual Foundations of Obsessive-Compulsive Spectrum Disorders," <i>Obsessive-Compulsive Disorder: Theory, Research, and Treatment</i> , 1998, pp. 397-425, Part III, Ch. 17, Pub: The Guilford Press, New York London, Div. Of Guilford Publications, Inc. (eds. Swinson, R.P., et al.), New York.			
PS	R12	GUPTA, B.K., et al., "Carbamazepine for Intermittent Explosive Disorder in a Prader-Willi Syndrome Patient," <i>J Clin Psychiatry</i> , 1987, p. 423, vol. 48, no. 10, Pub: Unknown.			

Examiner Signature	Phyllis Spivack	Date Considered	9/3/03
--------------------	-----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/997,447	
			Filing Date	November 30, 2001	
			First Named Inventor	Nathan Andrew Shapira	
			Group Art Unit	1614	
Examiner Name	(Unassigned)				
Attorney Docket Number	UF-260XC1				
Sheet	3	of	4		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article; (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
PS	R13	HALLER, R. and HINTERHUBER, H., "Treatment of Pathological Gambling with Carbamazepine," <i>Pharmacopsychiatry</i> , 1994, p. 129, vol. 27, no. 3, Pub: Georg Thieme Verlag Stuttgart, New York		
PS	R14	IRELAND, J.L., "A Descriptive Analysis of Self-Harm Reports Among a Sample of Incarcerated Adolescent Males," <i>J. Adolescence</i> , 2000, pp. 605-13, vol. 23, Pub: Association for Professionals in Services for Adolescents		
PS	R15	JONES, M.W., "Topiramate - Safety and Tolerability," <i>Can. J. Neurol. Sci.</i> , 1998, pp. S13-S15, vol. 25, Suppl. 3, Pub: Unknown, Canada		
PS	R16	KMETZ, G.F., et al., "Response of Kleptomania and Mixed Mania to Valproate," <i>Am J Psychiatry</i> , 1997, pp. 580-1, vol. 154, no. 4, Pub: Unknown		
PS	R17	KO, S.M., "Under-Diagnosed Psychiatric Syndrome II: Pathologic Skin Picking," <i>Annals Academy of Medicine Singapore</i> , 1999, pp. 557-9, vol. 28, no. 4, Pub: Unknown, Singapore		
PS	R18	LINDGREN, A.C., et al., "Effects of Growth Hormone Treatment on Growth and Body Composition in Prader-Willi Syndrome: A Preliminary Report. The Swedish National Growth Hormone Advisory Group," <i>Acta Paediatr Suppl.</i> , 1997, pp. 60-62, vol. 423, Pub: Scandinavian University Press		
PS	R19	MARCOTTE, D., "Use of Topiramate, a New Anti-Epileptic as a Mood Stabilizer," <i>Journal of Affective Disorders</i> , 1998, pp. 245-251, vol. 50, Pub: Elsevier Science B.V.		
PS	R20	MARTIN, A., et al., "Prader-Willi Syndrome," <i>Clinical Case Conference</i> , 1998, pp. 1265-1273, Pub: Unknown		
PS	R21	MARTIN, R., et al., "Cognitive Effects of Topiramate, Gabapentin, and Lamotrigine in Healthy Young Adults," <i>Neurology</i> , 1999, pp. 321-327, vol. 52, Pub: American Academy of Neurology		
PS	R22	McELROY, S.L., et al., "Open-Label Adjunctive Topiramate in the Treatment of Bipolar Disorders," <i>Biol. Psychiatry</i> , 2000, pp. 1025-33, vol. 47, Pub: Society of Biological Psychiatry		
PS	R23	MIKATI, M.A., et al., "Gabapentin in the Treatment of Refractory Partial Epilepsy in Children with Intellectual Disability," <i>J. Intellectual Disability Research</i> , 1998, pp. 57-62, vol. 42, Suppl. 1, Pub: Blackwell Science Ltd.		
PS	R24	MITCHELL, W.G., et al., "Effects of Antiepileptic Drugs on Reaction Time, Attention, and Impulsivity in Children," <i>Pediatrics</i> , 1993, pp. 101-105, vol. 91, no. 1, Pub: American Academy of Pediatrics		

Examiner Signature	<i>Phyllis Spivack</i>	Date Considered	9/3/03
--------------------	------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/997,447
Filing Date	November 30, 2001
First Named Inventor	Nathan Andrew Shapira
Group Art Unit	1614
Examiner Name	(Unassigned)
Attorney Docket Number	UF-260XC1

Sheet

4

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Ps	R25	MITCHELL, W.G., et al., "Reaction Time, Attention, and Impulsivity in Epilepsy," <i>Pediatric Neurology</i> , 1992, pp. 19-24, vol. 8, no. 1, Pub: Unknown	
Ps	R26	NEZIROGLU, F., et al., "Skin Picking as a Form of Self-Injurious Behavior," <i>Psychiatric Annals</i> , 2001, pp. 549-55, vol. 31, no. 9, Pub: Unknown	
Ps	R27	PERSINGER, M.A., "Subjective Improvement Following Treatment with Carbamazepine (Tegretol) for a Subpopulation of Patients with Traumatic Brain Injuries," <i>Perceptual and Motor Skills</i> , 2000, pp. 37-40, vol. 90, Pub: Perceptual and Motor Skills 2000	
Ps	R28	PRIVITERA, M., et al., "Topiramate Placebo-Controlled Dose-Ranging Trial in Refractory Partial Epilepsy Using 600-, 800-, and 1,000-mg Daily Dosages," <i>Neurology</i> , 1996, pp. 1678-1683, vol. 46, Pub: American Academy of Neurology	
Ps	R29	ROACH, E.S., et al., "Carbamazepine Trial for Lesch-Nyhan Self-Mutilation," <i>J. Child Neurology</i> , 1996, pp. 476-478, vol. 11, no. 6, Pub: Unknown	
Ps	R30	ROSENFELD, W.E., et al., "Comparison of the Steady-State Pharmacokinetics of Topiramate and Valproate in Patients with Epilepsy During Monotherapy and Concomitant Therapy," <i>Epilepsia</i> , 1997, pp. 324-333, vol. 38, no. 3, Pub: Lippincott-Raven Publishers, Philadelphia, © Int'l League Against Epilepsy	
Ps	R31	RUEDRICH, S., et al., "Effect of Divalproex Sodium on Aggression and Self-Injurious Behaviour in Adults with Intellectual Disability: A Retrospective Review," <i>Journal of Intellectual Disability Research</i> , 1999, pp. 105-111, vol. 43, part 2, Pub: Blackwell Science Ltd.	
Ps	R32	SELIKOWITZ, M., et al., "Fenfluramine in Prader-Willi Syndrome: A Double Blind, Placebo Controlled Trial," 1989, Pub: Unknown, Australia	
Ps	R33	SHAPIRA, N.A., et al., "Open-Label Pilot Study of Topiramate in Adults with Prader-Willi Syndrome." <i>ACNP - American College of Neuropsychopharmacology - Scientific Abstract: 39th Annual Meeting</i> , 2000, p. 271, Poster Session II, #71 - abstract and poster, Pub: American College of Neuropsychopharmacology	
Ps	R34	SILVA, R.R., et al., "Carbamazepine Use in Children and Adolescents with Features of Attention-Deficit Hyperactivity Disorder: A Meta-Analysis," <i>J. Am. Acad. Child Adolesc. Psychiatry</i> , 1996, pp. 352-358, vol. 35, no. 3, Pub: American Academy of Child and Adolescent Psychiatry	
Ps	R35	THOMPSON, P.J., et al., "Effects of Topiramate on Cognitive Function," <i>J Neurol Neurosurg Psychiatry</i> , 2000, pp. 636-641, vol. 69, Pub: Unknown, United Kingdom	
Ps	R36	WILHELM, S., et al., "Self-Injurious Skin Picking: Clinical Characteristics and Comorbidity," <i>J Clin Psychiatry</i> , 1999, pp. 454-459, vol. 60, no. 7, Pub: Unknown, Massachusetts	
	R37		

Examiner Signature

Phyllis Spivack

Date

Considered

9/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/997,447
 Filing Date November 30, 2001
 First Named Inventor Nathan Andrew Shapira
 Group Art Unit 1614
 Examiner Name
 Attorney Docket Number UF-260XC1 *Spivack*

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	PRADER, A. et al., "Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myatonieartigem Zustand im Neugeborenenalter," Schweizerische Medizinische Wochenschrift Nr. 44, 1956, Pub. unknown, Germany [article is in German]	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/997,447
Filing Date	November 30, 2001
First Named Inventor	Nathan A. Shapira
Art Unit	1614
Examiner Name	SPINACK
Attorney Docket Number	UF-260XC1

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
DS	F1	WO 00/50020 / A2	08-31-2000	University of Cincinnati	All	
PS	F2	WO 00/48549 / A2	08-24-2000	Ortho-McNeil Pharmaceutical, Inc.	All	
PS	F3	WO 98/00131 / A1	01-08-1998	Ortho Pharmaceutical Corporation	All	
PS	F4	WO 98/15270 / A1	04-16-1998	Ortho Pharmaceutical Corporation	All	
PS	F5	WO 00/23059 / A2	04-27-2000	Ortho-McNeil Pharmaceutical, Inc.	All	
PS	F6	WO 00/28945 / A2	05-25-2000	Ortho-McNeil Pharmaceutical, Inc.	All	
PS	F7	WO 00/76493 / A1	12-21-2000	Thomas Najarian	All	
PS	F8	WO 98/00129 / A2	01-08-1998	Ortho Pharmaceutical Corporation	All	

Examiner
Signature

Phyllis Spinack

Date
Considered

9/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Application Number

09/997,447

Filing Date

November 30, 2001

First Named Inventor

Nathan Andrew Shapira

Art Unit

1614

Examiner Name

Attorney Docket Number

UF-260XC1

Spivack

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
JS	U1	US-6,462,084	10/08/2002	Dewey et al.	
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner
Signature

Phillip Spivack

Date
Considered

9/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.